60 Degrees Pharm Stock Price, News & Analysis

60 Degrees Pharmaceuticals, Inc. (warrants trading under the symbol SXTPW) is a specialty pharmaceutical company that focuses on the treatment and prevention of infectious, vector-borne diseases. According to company disclosures and regulatory filings, 60 Degrees Pharmaceuticals applies biological science and clinical research to develop and commercialize medicines that address malaria and tick-borne illnesses such as babesiosis. Its common stock trades on The Nasdaq Capital Market under the symbol SXTP, and its warrants are listed under SXTPW.

The company, often referred to as “60 Degrees Pharma,” was founded in 2010 and is headquartered in Washington, D.C., with a subsidiary in Australia. Public statements note that the company collaborates with research and academic organizations in the United States and Australia, and, in some communications, Singapore. These collaborations support both clinical development and scientific studies in vector-borne diseases.

Core business and lead product

60 Degrees Pharmaceuticals reports that it specializes in developing and commercializing new medicines for the treatment and prevention of vector-borne disease. The company’s lead product is ARAKODA® (tafenoquine), an antimalarial drug. Company news releases state that 60 Degrees Pharmaceuticals achieved U.S. Food and Drug Administration (FDA) approval of ARAKODA for malaria prevention in 2018. ARAKODA is described as being commercially available in the U.S. and Australia, distributed through pharmaceutical wholesaler networks and dispensed as a prescription-only malaria prevention drug at retail pharmacies.

Public materials explain that tafenoquine, the active ingredient in ARAKODA, was discovered by the Walter Reed Army Institute of Research. The company notes that ARAKODA is indicated for the prophylaxis of malaria in adults and that its safety for malaria prophylaxis has been evaluated in multiple randomized, double-blind, active comparator or placebo-controlled trials of up to six months’ duration. Safety information released by the company highlights contraindications (including glucose-6-phosphate dehydrogenase deficiency, certain psychiatric histories, and hypersensitivity to tafenoquine or related compounds), as well as warnings about hemolytic anemia, methemoglobinemia, psychiatric effects, hypersensitivity reactions, and delayed adverse reactions due to tafenoquine’s long half-life.

Focus on babesiosis and vector-borne disease research

In addition to malaria prevention, 60 Degrees Pharmaceuticals has publicly described a strategic focus on babesiosis, an emerging tick-borne illness caused by Babesia parasites. Company announcements describe babesiosis as an orphan disease with symptoms such as fevers, chills, sweats, and fatigue, and note that it can be life-threatening in elderly and immunosuppressed patients. The company cites insurance claims research it commissioned suggesting that the minimum annual incidence of babesiosis in the United States is at least 25,000 cases per year, while acknowledging that the true number may be higher. Company communications also state that no FDA-approved treatment currently exists specifically for babesiosis.

60 Degrees Pharmaceuticals sponsors several clinical trials to evaluate tafenoquine in babesiosis. Public descriptions reference three studies (NCT06478641, NCT06207370, and NCT06656351) that examine tafenoquine’s safety and efficacy in different babesiosis patient populations, including hospitalized patients and those with relapsing or chronic disease. The company emphasizes that tafenoquine has not been proven to be effective for treatment or prevention of babesiosis and is not approved by the FDA for that indication. These studies are described as part of a broader effort to understand the role of Babesia infection in chronic fatigue and related conditions, and to explore potential therapeutic options where unmet medical need is high.

B-FREE Chronic Babesiosis Study and clinical collaborations

Company news releases describe the B-FREE Chronic Babesiosis Study (NCT06656351) as an open-label Phase 2 trial that evaluates the efficacy and safety of the ARAKODA regimen of tafenoquine over 90 days in patients with chronic babesiosis. The primary endpoint is reported as the resolution of fatigue, measured using a patient-reported outcome tool. The study is designed to enroll up to 100 patients and includes extensive molecular testing to confirm Babesia infection and track eradication over time.

60 Degrees Pharmaceuticals reports that the Cohen Center for Recovery from Complex Chronic Diseases at the Icahn School of Medicine at Mount Sinai in New York City serves as a central site for the B-FREE study. The company has also publicized a sponsored research agreement with Tulane University to evaluate activity of tafenoquine against other pathogens such as Borrelia (associated with Lyme disease) and Bartonella. These collaborations are presented as examples of the company’s engagement with institutions that have expertise in infectious and tick-borne diseases.

Commercial activities and market focus

Company communications describe 60 Degrees Pharmaceuticals as developing and marketing medicines for vector-borne diseases. For ARAKODA, the company has discussed commercial initiatives such as a six-month pilot program to assess prescriber demand, expansion of its inside sales team, and an agreement with GoodRx to broaden visibility of a point-of-sale offer. It has also referenced an integrated digital marketing campaign aimed at prescribers.

In its public updates, the company has indicated that it is exploring additional indications and markets, including a potential Minor Use Minor Species (MUMS) designation from the FDA for treatment of acute canine babesiosis. The company has also disclosed internal and commissioned research to estimate the total addressable market for babesiosis treatment, though these estimates are subject to change and are tied to specific timeframes and assumptions.

Regulatory and capital markets profile

According to SEC filings, 60 Degrees Pharmaceuticals is incorporated in Delaware and classified under the standard industrial classification code associated with medicinal and botanical manufacturing. The company identifies itself as an emerging growth company and a smaller reporting company. Its common stock (SXTP) and warrants (SXTPW) are listed on The Nasdaq Stock Market LLC. An 8-K filing dated September 3, 2025, describes an at-the-market sales agreement with a placement agent for potential issuance of additional common shares, and also notes the termination of a prior at-the-market agreement with another firm.

A registration statement on Form S-1 filed in July 2025 outlines a proposed offering of common stock, pre-funded warrants, and series A-1 and A-2 warrants, along with placement agent warrants. The prospectus describes the terms of these securities, including exercise conditions and the use of proceeds for general corporate purposes and working capital. The company has also disclosed a reverse stock split of its common stock, and a later press release describes a one-for-four reverse stock split intended to help the company comply with Nasdaq’s minimum bid price requirement, with trading on a post-split basis under the existing SXTP symbol.

Geographic footprint and partnerships

Public statements consistently note that 60 Degrees Pharmaceuticals is headquartered in Washington, D.C. and maintains a subsidiary in Australia. The company reports that ARAKODA is available in both the U.S. and Australia, and that it works with research and academic partners in these countries. In some communications, it also mentions collaborations with organizations in Singapore. The company has highlighted support from the U.S. Department of Defense in the form of in-kind funding, and has referenced private institutional investors, including Knight Therapeutics Inc., as having supported its mission.

Risk, safety, and regulatory considerations

Because 60 Degrees Pharmaceuticals operates in the pharmaceutical sector, its public communications include extensive risk disclosures and safety information. For ARAKODA, the company provides detailed prescribing and safety information, including contraindications, warnings, and common adverse reactions such as headache, dizziness, gastrointestinal symptoms, and sleep or mood-related effects. It emphasizes the need for G6PD testing before prescribing tafenoquine and notes that certain adverse reactions may be delayed due to the drug’s long half-life.

For its babesiosis program, the company stresses that tafenoquine is not approved by the FDA for treatment or prevention of babesiosis and that ongoing studies are intended to evaluate safety and efficacy in specific patient populations. The company also includes standard forward-looking statement disclaimers in its news releases and SEC filings, noting that actual results may differ from expectations due to known and unknown risks and uncertainties.

Position within the medicinal and botanical manufacturing sector

Within the broader medicinal and botanical manufacturing industry, 60 Degrees Pharmaceuticals presents itself as a company focused on vector-borne infectious diseases, particularly malaria and babesiosis. Its activities span drug development, regulatory approval, clinical research, and commercialization. The presence of listed common stock and warrants on Nasdaq, along with multiple clinical programs and collaborations with academic institutions, are key structural features of the business as described in its public disclosures.

Frequently asked questions (FAQ)

• What does 60 Degrees Pharmaceuticals, Inc. do?
  According to company statements, 60 Degrees Pharmaceuticals specializes in developing and commercializing new medicines for the treatment and prevention of vector-borne diseases, including malaria and babesiosis.
• What is the relationship between SXTP and SXTPW?
  SEC filings indicate that SXTP is the trading symbol for 60 Degrees Pharmaceuticals’ common stock on The Nasdaq Stock Market LLC, while SXTPW is the symbol for warrants, each warrant entitling the holder to purchase one share of common stock, subject to the terms of the relevant warrant agreements.
• Where is 60 Degrees Pharmaceuticals headquartered?
  Public disclosures state that 60 Degrees Pharmaceuticals is headquartered in Washington, D.C., with a subsidiary in Australia.
• What is ARAKODA (tafenoquine)?
  Company materials describe ARAKODA (tafenoquine) as an antimalarial drug approved by the U.S. Food and Drug Administration for the prophylaxis of malaria in adults. It is commercially available in the United States and Australia as a prescription-only malaria prevention medicine.
• Is tafenoquine approved for babesiosis?
  No. The company explicitly states that tafenoquine has not been proven to be effective for the treatment or prevention of babesiosis and is not approved by the U.S. Food and Drug Administration for that indication.
• What are the B-FREE and other babesiosis studies?
  Public announcements describe B-FREE (NCT06656351) as an open-label Phase 2 study evaluating the efficacy and safety of the ARAKODA regimen of tafenoquine over 90 days in patients with chronic babesiosis. Two additional company-sponsored studies (NCT06478641 and NCT06207370) are reported to evaluate tafenoquine in other babesiosis settings, including hospitalized and relapsing patients.
• When was 60 Degrees Pharmaceuticals founded?
  Company descriptions state that 60 Degrees Pharmaceuticals, Inc. was founded in 2010.
• On which exchange are 60 Degrees Pharmaceuticals’ securities listed?
  SEC filings report that the company’s common stock (SXTP) and warrants (SXTPW) are listed on The Nasdaq Stock Market LLC.
• What sector and industry is 60 Degrees Pharmaceuticals in?
  Based on provided classifications, 60 Degrees Pharmaceuticals operates in the Manufacturing sector, within the medicinal and botanical manufacturing industry.
• Has the company undertaken any reverse stock splits?
  Company communications describe a one-for-four reverse stock split of its common stock, intended to help the company meet Nasdaq’s minimum bid price requirement, with trading to continue under the existing SXTP symbol on a post-split basis.